NCT05302973 is a NA clinical trial of Conventional rehabilitation in COVID-19, sponsored by Istituti Clinici Scientifici Maugeri SpA.

Who is sponsoring NCT05302973?

NCT05302973 is sponsored by Istituti Clinici Scientifici Maugeri SpA.

What drugs are being tested in NCT05302973?

Interventions in NCT05302973: Conventional rehabilitation, Aerobic exercise.

Is NCT05302973 still recruiting?

NCT05302973 is currently completed. Last updated 21 July 2023.

Last reviewed 2023-07-21 · How we verify

NCT05302973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aerobic Exercise in People With Post-COVID-19

Completed NA Last updated 21 July 2023

What this trial tests

NA trial testing Conventional rehabilitation in COVID-19 in 30 participants. Completed in 10 July 2023.

Timeline

22 November 2021

Primary endpoint
31 December 2022

10 July 2023

Quick facts

Lead sponsor	Istituti Clinici Scientifici Maugeri SpA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	22 November 2021
Primary completion	31 December 2022
Estimated completion	10 July 2023
Sites	1 location across Italy

Drugs / interventions tested

Conventional rehabilitation
Aerobic exercise — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Istituti Clinici Scientifici Maugeri SpA

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to study the feasibility of an aerobic training, in addition to conventional rehabilitation, in patients post sequela of interstitial pneumonia due to COVID-19. In particular, we wish to verify if patients could tolerate this kind of physical activity and if there are any adverse effects. The secondary aim is to evaluate if the aerobic exercise is effective in improving functional capacity and gait performance in these patients respect to the common physiotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Aerobic Training in Patients with Subacute COVID-19: A Randomized Controlled Feasibility Trial.
Corna S, Giardini M, Godi M, Bellotti L, et al · · 2022 · cited 6× · PMID 36554262 · DOI 10.3390/ijerph192416383

Verify or expand the search:

Other trials of Conventional rehabilitation

Trials testing the same drug.

NCT07292428 — Cognitive-motor Technology Rehabilitation in Frail Individuals · NA · recruiting
NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
NCT07132762 — The Effect of ESWT Added to Conservative Treatment on Pain, Disability, and Ultrasonographic Outcomes in Chronic Low Bac · NA · recruiting
NCT07119801 — Clinical and Ultrasonographic Evaluation of the Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Post-Stroke Spas · NA · recruiting
NCT07299162 — The Effect of Virtual Reality Therapy on Upper Extremity Functions in Subacute Stroke Patients Receiving Rehabilitation · NA · recruiting

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Istituti Clinici Scientifici Maugeri SpA trials

Trials by the same sponsor.

NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05302973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
Last refreshed: 21 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05302973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing